Cipla has announced the launch of Ciplostem Knee Osteoarthritis Therapy, a next-generation cell-based therapy designed specifically for Knee Osteoarthritis (OA). This advancement signals a major step forward in India’s orthobiologic treatment ecosystem. With approval from the Drug Controller General of India (DCGI), the therapy offers a disease-modifying solution for individuals diagnosed with Grade II and III OA, providing longer and more meaningful relief compared to traditional symptomatic treatments.

Thank you for reading this post, don't forget to subscribe!

A Revolutionary Step in Regenerative Orthobiologics

Created in collaboration with Stempeutics Research, Ciplostem marks Cipla’s strategic entry into the field of regenerative medicine. By focusing on cellular repair and inflammation control, the therapy aims to fill a critical therapeutic gap in India—where millions suffer from progressing knee deterioration and often lack effective long-term treatment options.

Growing Impact of Knee Osteoarthritis in India

More than 48 million Indians are affected by Knee Osteoarthritis, with cases increasingly seen in younger individuals due to lifestyle factors and injury. Current management options such as painkillers, physiotherapy, and viscosupplements generally offer short-lived benefits. The absence of durable and disease-modifying care has created strong demand for innovative solutions that delay or possibly avoid surgery—exactly where Ciplostem Knee Osteoarthritis Therapy holds promise.

How Ciplostem Works and Its Clinical Significance

Administered as a single intra-articular injection, Ciplostem acts at the cellular level to:

Reduce inflammation
Relieve pain
Support cartilage preservation
Improve mechanical joint function

Clinical outcomes suggest benefits may last up to two years, representing a significant improvement over conventional pain-management therapies.

Key Points for Exams

Developed by Stempeutics Research and marketed by Cipla
Approved for Grade II and Grade III Knee Osteoarthritis
Authorized by DCGI for clinical use in India
Therapeutic benefits observed for up to two years

Future Outlook and Medical Adoption of Ciplostem Knee Osteoarthritis Therapy

Cipla anticipates widespread integration of Ciplostem into orthopaedic practice as a validated regenerative treatment. By delivering long-term symptom relief and protecting cartilage health, Ciplostem Knee Osteoarthritis Therapy has the potential to reduce dependency on invasive surgical interventions and transform how chronic knee degeneration is managed across India.